Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson's Disease.
IL-1β
astrocyte
cannabidiol
dopamine
glutamate
microglia
neuroinflammation, TNF-α
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
10
2020
accepted:
27
11
2020
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
30
1
2021
Statut:
epublish
Résumé
Our present objective was to better characterize the mechanisms that regulate striatal neuroinflammation in mice developing L-DOPA-induced dyskinesia (LID). For that, we used 6-hydroxydopamine (6-OHDA)-lesioned mice rendered dyskinetic by repeated intraperitoneal injections of 3,4-dihydroxyphenyl-L-alanine (L-DOPA) and quantified ensuing neuroinflammatory changes in the dopamine-denervated dorsal striatum. LID development was associated with a prominent astrocytic response, and a more moderate microglial cell reaction restricted to this striatal area. The glial response was associated with elevations in two pro-inflammatory cytokines, tumor necrosis factor-α (TNF-α) and interleukin-1β. Treatment with the phytocannabinoid cannabidiol and the transient receptor potential vanilloid-1 (TRPV-1) channel antagonist capsazepine diminished LID intensity and decreased TNF-α levels without impacting other inflammation markers. To possibly reproduce the neuroinflammatory component of LID, we exposed astrocyte and microglial cells in culture to candidate molecules that might operate as inflammatory cues during LID development, i.e., L-DOPA, dopamine, or glutamate. Neither L-DOPA nor dopamine produced an inflammatory response in glial cell cultures. However, glutamate enhanced TNF-α secretion and GFAP expression in astrocyte cultures and promoted Iba-1 expression in microglial cultures. Of interest, the antidyskinetic treatment with cannabidiol + capsazepine reduced TNF-α release in glutamate-activated astrocytes. TNF-α, on its own, promoted the synaptic release of glutamate in cortical neuronal cultures, whereas cannabidiol + capsazepine prevented this effect. Therefore, we may assume that the release of TNF-α by glutamate-activated astrocytes may contribute to LID by exacerbating corticostriatal glutamatergic inputs excitability and maintaining astrocytes in an activated state through a self-reinforcing mechanism.
Identifiants
pubmed: 33510643
doi: 10.3389/fphar.2020.617085
pii: 617085
pmc: PMC7836015
doi:
Types de publication
Journal Article
Langues
eng
Pagination
617085Informations de copyright
Copyright © 2021 dos Santos Pereira, de Abreu, Rocca, Hamadat, Raisman-Vozari, Michel and Del Bel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurobiol Dis. 2006 Jun;22(3):586-98
pubmed: 16531050
Mov Disord. 2018 Oct;33(10):1632-1642
pubmed: 29756234
Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78
pubmed: 23108553
J Clin Invest. 2020 May 1;130(5):2593-2601
pubmed: 32310223
Brain Res Brain Res Rev. 2005 Apr;48(2):133-43
pubmed: 15850652
Behav Brain Res. 2005 Jul 1;162(1):1-10
pubmed: 15922062
Nat Neurosci. 2002 May;5(5):405-14
pubmed: 11953750
Neurobiol Dis. 2015 Feb;74:295-304
pubmed: 25486547
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Apr 3;75:94-105
pubmed: 27889412
Exp Neurol. 2005 Jul;194(1):66-75
pubmed: 15899244
Neurobiol Dis. 2004 Mar;15(2):171-6
pubmed: 15006686
Prog Neurobiol. 2012 Jan;96(1):69-86
pubmed: 22075179
J Neural Transm (Vienna). 2018 Aug;125(8):1225-1236
pubmed: 29387966
Mediators Inflamm. 2014;2014:861231
pubmed: 24966471
Glia. 2020 Jul;68(7):1396-1409
pubmed: 32003513
Biol Psychiatry. 2009 Sep 15;66(6):603-13
pubmed: 19520364
Glia. 2016 Nov;64(11):1912-24
pubmed: 27452488
PLoS One. 2015 Oct 28;10(10):e0141249
pubmed: 26509840
Neurobiol Dis. 2003 Dec;14(3):404-16
pubmed: 14678757
Eur J Neurosci. 2017 Jan;45(1):73-91
pubmed: 27859864
J Pharmacol Exp Ther. 2009 Jul;330(1):227-35
pubmed: 19357321
Neurobiol Dis. 2016 Oct;94:179-95
pubmed: 27373843
Biol Psychiatry. 2015 Jan 15;77(2):95-105
pubmed: 24857398
Schizophr Res. 2015 May;164(1-3):155-63
pubmed: 25680767
Glia. 2020 Mar;68(3):561-573
pubmed: 31647138
Neurobiol Dis. 2002 Jul;10(2):165-86
pubmed: 12127155
J Neural Transm (Vienna). 2018 Aug;125(8):1287-1297
pubmed: 29541852
Trends Biochem Sci. 2016 Dec;41(12):1012-1021
pubmed: 27669650
J Neurochem. 2008 Jul;106(2):746-56
pubmed: 18419760
Cell Death Discov. 2016 May 16;2:16018
pubmed: 27551511
Nat Neurosci. 2003 May;6(5):501-6
pubmed: 12665799
Biol Psychiatry. 2006 Jan 1;59(1):64-74
pubmed: 16139809
Eur J Neurosci. 2014 Mar;39(6):1042-56
pubmed: 24372914
FEBS Lett. 2014 Aug 25;588(17):2952-6
pubmed: 24911209
Parkinsonism Relat Disord. 2007;13 Suppl 3:S263-7
pubmed: 18267248
Cell. 2015 Jan 15;160(1-2):62-73
pubmed: 25594175
Front Neurol. 2014 Aug 05;5:144
pubmed: 25140165
Brain Behav Immun. 2018 Nov;74:241-251
pubmed: 30217539
Synapse. 2016 Dec;70(12):479-500
pubmed: 27618286
Neuroscience. 2015 Apr 2;290:492-508
pubmed: 25644418
Prog Brain Res. 2010;183:209-33
pubmed: 20696322
J Neurochem. 2013 Jun;125(6):897-908
pubmed: 23578284
Neurobiol Dis. 2015 Jan;73:377-87
pubmed: 25447229
Neuropharmacology. 2016 Aug;107:432-450
pubmed: 27016022
J Neural Transm (Vienna). 2018 Aug;125(8):1237-1250
pubmed: 29511826
J Neuropathol Exp Neurol. 2009 Oct;68(10):1092-102
pubmed: 19918121
Eur J Neurosci. 2004 Sep;20(5):1255-66
pubmed: 15341597
Int Immunopharmacol. 2009 Feb;9(2):216-22
pubmed: 19070683
Brain Res. 2002 Feb 1;926(1-2):149-55
pubmed: 11814417
Neuroscience. 2008 Sep 22;156(1):30-41
pubmed: 18687386
Front Neurosci. 2019 Aug 02;13:769
pubmed: 31440123
Exp Neurol. 2016 Dec;286:83-92
pubmed: 27697481
Neurotox Res. 2016 May;29(4):447-59
pubmed: 26745968
PLoS One. 2013;8(2):e55706
pubmed: 23390548
Philos Trans R Soc Lond B Biol Sci. 2015 Jul 5;370(1672):
pubmed: 26009769
Glia. 2018 Nov;66(11):2353-2365
pubmed: 30394585
Front Neurol. 2014 Dec 15;5:242
pubmed: 25566170
Neurotox Res. 2020 Jan;37(1):12-29
pubmed: 31637586